Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 13/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467213 | 0.92 | LMNA (0.38) | LMNAHTTSMN1; SMN2MAPTCTSS | |
| SCHEMBL6463875 | 0.91 | CTSS (0.39) | LMNAHTTSMN1; SMN2MAPTCTSS | |
| SCHEMBL7183175 | 0.91 | CTSS (0.39) | LMNAHTTSMN1; SMN2MAPTCTSS | |
| SCHEMBL6062088 | 0.90 | CTSS (0.36) | LMNAHTTSMN1; SMN2CTSSCYP3A4 | |
| SCHEMBL6062750 | 0.82 | EPHX2 (0.38) | LMNAHTTMAPTCTSSCYP3A4 | |
| SCHEMBL6464521 | 0.79 | CTSS (0.38) | LMNAHTTSMN1; SMN2CTSSCYP3A4 | |
| SCHEMBL6468767 | 0.77 | CTSS (0.36) | CTSSCYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL7044831 | 0.77 | CTSS (0.36) | CTSSCYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL7044345 | 0.76 | CTSS (0.39) | LMNAHTTSMN1; SMN2MAPTCTSS | |
| SCHEMBL7179327 | 0.76 | LMNA (0.38) | LMNAHTTSMN1; SMN2CTSSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | LMNA 1755/4885HTT 2464/4885SMN1; SMN2 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.